Zacks: Brokerages Expect Theravance Biopharma Inc (NASDAQ:TBPH) to Post -$1.22 Earnings Per Share
Wall Street analysts expect Theravance Biopharma Inc (NASDAQ:TBPH) to report ($1.22) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Theravance Biopharma’s earnings. The highest EPS estimate is ($1.11) and the lowest is ($1.30). Theravance Biopharma posted earnings per share of ($0.76) in the same quarter last year, which indicates a negative year-over-year growth rate of 60.5%. The business is expected to report its next quarterly earnings report on Wednesday, August 7th.
On average, analysts expect that Theravance Biopharma will report full year earnings of ($4.74) per share for the current financial year, with EPS estimates ranging from ($5.20) to ($4.03). For the next financial year, analysts forecast that the business will report earnings of ($4.27) per share, with EPS estimates ranging from ($5.76) to ($3.28). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by ($0.14). Theravance Biopharma had a negative net margin of 388.61% and a negative return on equity of 2,631.71%. The business had revenue of $5.34 million during the quarter, compared to analyst estimates of $16.45 million.
In other Theravance Biopharma news, Director Donal O’connor sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $20.46, for a total value of $81,840.00. Following the completion of the sale, the director now owns 30,244 shares of the company’s stock, valued at $618,792.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.60% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in Theravance Biopharma by 0.8% during the fourth quarter. BlackRock Inc. now owns 3,863,076 shares of the biopharmaceutical company’s stock worth $98,857,000 after acquiring an additional 29,667 shares during the period. Norges Bank bought a new stake in shares of Theravance Biopharma during the 4th quarter valued at $22,422,000. Northern Trust Corp raised its stake in shares of Theravance Biopharma by 0.8% during the 4th quarter. Northern Trust Corp now owns 550,796 shares of the biopharmaceutical company’s stock valued at $14,095,000 after purchasing an additional 4,274 shares during the period. Geode Capital Management LLC grew its position in Theravance Biopharma by 9.4% during the first quarter. Geode Capital Management LLC now owns 544,029 shares of the biopharmaceutical company’s stock worth $12,333,000 after buying an additional 46,805 shares in the last quarter. Finally, Chescapmanager LLC grew its position in Theravance Biopharma by 1.5% during the fourth quarter. Chescapmanager LLC now owns 414,921 shares of the biopharmaceutical company’s stock worth $10,618,000 after buying an additional 6,000 shares in the last quarter. Institutional investors and hedge funds own 84.75% of the company’s stock.
NASDAQ TBPH opened at $15.95 on Tuesday. Theravance Biopharma has a 52 week low of $15.18 and a 52 week high of $35.48.
About Theravance Biopharma
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
See Also: How Short Selling Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.